HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma
| Autor: | M. Dolores Caballero, Luis Marín, Carlos Grande, Cristina Jimenez, M. Eugenia Sarasquete, Jesús F. San Miguel, Eva González-Barca, Alejandro Martín, Jose Luis Bello, M. Carmen Chillón, Ramón García-Sanz, Miguel Alcoceba, Carlos Panizo, Fatima De la Cruz, Marcos González, Carmen Albo, Rocío Corral, Elena Sebastián, Emilia Pardal, Ana Balanzategui, Noemi Puig |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Vincristine Adolescent Prednisolone Immunology CHOP Biochemistry Disease-Free Survival Antibodies Monoclonal Murine-Derived Young Adult International Prognostic Index Gene Frequency HLA Antigens Risk Factors immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine HLA-B Antigens Humans Cyclophosphamide Aged Aged 80 and over Polymorphism Genetic business.industry Cell Biology Hematology Middle Aged Prognosis medicine.disease Lymphoma Regimen Phenotype Doxorubicin Case-Control Studies Female Rituximab Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma HLA-DRB1 Chains medicine.drug |
| Zdroj: | Blood. 122:1448-1454 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2013-02-483420 |
| Popis: | Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease influenced by genetic and environmental factors. The role of the HLA system in tumor antigen presentation could be involved in susceptibility and disease control. We analyzed the phenotypic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 in 250 DLBCLs, comparing them with 1940 healthy individuals. We also evaluated the influence of HLA polymorphisms on survival in those patients treated with curative intention using cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen without (n = 64, 26%) or with (n = 153, 61%) rituximab. DLBCL patients have a higher phenotypic frequency of HLA-DRB1*01 (29% vs 19.5%, P = .0008, Pc = .0104) and a lower frequency of HLA-C*03 (6.4% vs 17.9%, P < .0005, Pc = .007) compared with healthy individuals. Irrespective of the age-adjusted International Prognostic Index, those patients receiving a CHOP-like plus rituximab regimen and carrying the HLA-B44 supertype had worse 5-year progression-free (54% vs 71%, P = .019) and 5-year overall (71% vs 92%, P = .001) survival compared with patients without this supertype. Our data suggest that some HLA polymorphisms influence the development and outcome of DLBCL, allowing the identification of an extremely good-risk prognostic subgroup. However, these results are preliminary and need to be validated in order to exclude a possible population effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|